Source-grounded facts extracted from Longeveron Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Marie Washburn changed role as Vice President and Corporate Controller at Longeveron Inc..
“Marie Washburn, who has been serving as Chief Financial Officer of the Company will remain with the Company in her prior role of Vice President and Corporate Controller.”
Nirav S. Jhaveri was appointed as Chief Financial Officer at Longeveron Inc..
“Longeveron Inc. (the “Company”) has appointed Nirav S. Jhaveri to serve as Chief Financial Officer, principal financial officer and principal accounting officer of the Company, effective August 17, 2026 (the “Effective Date”).”
Marie Washburn was appointed as Chief Financial Officer at Longeveron Inc..
“who the Company anticipates will be elevated into the CFO role upon Ms. Locklear’s departure (pending final contract).”
Lisa Locklear resigned as Chief Financial Officer at Longeveron Inc..
“On June 1, 2026, Ms. Lisa Locklear informed management of Longeveron Inc. (the “Company”) of her decision to step down as Chief Financial Officer, to become effective July 10, 2026.”
Longeveron Inc. reported financial results for three months ended March 31, 2026.
“Longeveron Inc. (the “Company”) issued a press release announcing its financial and operating results for the three months ended March 31, 2026”
Longeveron Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“March 24, 2026, the Company received a written notice from Nasdaq (the “March Notice”) granting an additional 180 days, or until September 21, 2026, to regain compliance with the Minimum Bid Price Requirement. If at any time before September 21, 2026, the closing bid price of the Company’s Common Stock is at least $1.00 per share for a minimum of ten consecutive business days, unless Nasdaq exercises its discretion to extend this ten-day period, Nasdaq will provide written confirmation stating that the Company has achieved compliance with the Minimum Bid Price Requirement. The March Notice has”
Longeveron Inc.: Filed Certificate of Designation for Series A Non-Voting Convertible Preferred Stock (effective 2026-03-10).
“On March 10, 2026, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of the Series A Non-Voting Convertible Preferred Stock with the Secretary of State of the State of Delaware (the “Certificate of Designation”) in connection with the Private Placement.”
Longeveron Inc. entered into Purchase Agreement with certain institutional and accredited investors (effective 2026-03-10).
“On March 10, 2026, Longeveron Inc., a Delaware corporation (the “Company”), entered into a Purchase Agreement (the “Purchase Agreement”) with certain institutional and accredited investors (each, an “Investor” and collectively, the “Investors”), pursuant to which the Company agreed to issue and sell shares of the Company’s Class A common stock, par value $0.001 per share (the “Common Stock”) and, shares of the Company’s Series A Non-Voting Convertible Preferred Stock, par value $0.001 per share, and stated value of $1,000 per share (the “Series A Preferred Stock,” and together with the Common Stock, the “Securities”) to the Investors in up to two closings in a private placement (the “Private Placement”).”
Longeveron Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2)(A), 5605(c)(2), 5605(c)(4)).
“March 4, 2026 Longeveron Inc. (the “Company”) notified Nasdaq that, as a result of the resignation of Mr. Richard Kender as a member of the Board of Directors (the “Board”) of the Company and as chairman of the Audit Committee and the audit committee financial expert, as described below, the Company temporarily was no longer in compliance with Nasdaq Listing Rule 5605(c)(2)(A), which requires that the audit committee of a listed company be composed of at least three independent directors and that at least one member qualifies as an audit committee financial expert. On March 4, 2026, the Compan”
Longeveron Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“September 22, 2025, Longeveron Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) that the Company’s Class A common stock (“Common Stock”) did not meet the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) as a result of the closing bid price of the Company’s Common Stock for the last 30 consecutive business days. The Notice does not result in the immediate delisting of the Company’s Common Stoc”
Longeveron Inc. engaged CBIZ CPAs P.C. as its auditor.
“On March 13, 2025, with the approval of the Company’s Audit Committee and Board of Directors, CBIZ was engaged as the Company’s new independent registered public accounting firm for the fiscal year ending December 31, 2025.”
Marcum LLP resigned as auditor of Longeveron Inc..
“On March 13, 2025, Longeveron Inc. (the "Company") was notified by Marcum LLP ("Marcum") that Marcum resigned as the Company’s independent registered public accounting firm.”
Neil Hare resigned as Director at Longeveron Inc..
“On January 27, 2025, Mr. Neil Hare provided notice of his resignation from the Board of Directors (the “Board”) of Longeveron Inc. (the “Company”) to be effective immediately.”
Richard Kender was appointed as Director at Longeveron Inc..
“On May 10, 2024, the Company’s Board appointed Richard Kender, age 68, to the Board as a Class II director, effective immediately, to fill the vacancy created by the resignation of Mr. Pfeffer.”
Cathy Ross resigned as Director at Longeveron Inc..
“On May 8, 2024, Cathy Ross gave notice of her resignation from the Board and from each committee of the Board, to be effective immediately.”
Jeffrey Pfeffer resigned as Director at Longeveron Inc..
“On May 6, 2024, Jeffrey Pfeffer gave notice of his resignation from the Board of Directors (the “Board”) of Longeveron Inc. (the “Company”) and from each committee of the Board, to be effective immediately.”
Longeveron Inc. entered into Inducement Letter Agreements with certain holders valued at approximately $6.2 million (effective 2024-04-16).
“On April 16, 2024, Longeveron Inc., a Delaware corporation (the “Company”), entered into inducement letter agreements (the “Inducement Letter Agreements”) with certain holders (the “Holders”) of its existing (i) Series A warrants to purchase up to an aggregate of 242,425 shares of the Company’s Class A common stock”
Longeveron Inc. amended Warrant Amendment Agreement with a holder (the “Holder”) of existing warrants (effective 2024-04-08).
“the Company also entered into an agreement (the “Warrant Amendment Agreement”) with a holder (the “Holder”) of existing warrants to purchase shares of the Company’s Common Stock to, in consideration for the Holder’s participation in the Offering and purchase of securities in the Offering, and contingent upon the closing of the Offering and the Holder’s participation in the Offering, amend the Holder’s existing warrants to purchase up to (a) 242,425 shares of common stock at an exercise price of $16.50 per share, issued on October 13, 2023 and expiring on April 13, 2029 (the “Series A Warrants”) and (b) 242,425 shares of common stock at an exercise price of $16.50 per share, issued on October 13, 2023 and expiring on April 14, 2025 (the “Series B Warrants” and together with the Series A Warrants, the “Existing Warrants”) to (i) reduce the Exercise Price (as defined in the Existing Warrants) of the Existing Warrants to $2.35 per share and (ii) amend the expiration date of the Series A Wa”
Longeveron Inc. entered into engagement letter with H.C. Wainwright & Co., LLC valued at 7.0% of the aggregate gross proceeds (effective 2024-03-01).
“As compensation to H.C. Wainwright & Co., LLC (the “Placement Agent”), pursuant to an engagement letter, dated as of March 1, 2024, as amended on April 3, 2024, and April 9, 2024, by and between the Company and the Placement Agent, pursuant to which the Placement Agent agreed to act as the exclusive placement agent in connection with the Offering, the Company paid the Placement Agent a cash fee equal to 7.0% of the aggregate gross proceeds raised in the Offering, plus a management fee equal to 1.0% of the aggregate gross proceeds raised in the Offering and certain expenses incurred in connection with the Offering.”
Longeveron Inc. entered into Purchase Agreement with certain institutional investors valued at approximately $5.20 million (effective 2024-04-08).
“Certain institutional investors purchasing securities as part of the Offering entered into a securities purchase agreement with the Company (the “Purchase Agreement”), dated as of April 8, 2024.”
Longeveron Inc.: Filed a certificate of amendment to the Certificate of Incorporation to effect a 1-for-10 reverse stock split, effective March 26, 2024 (effective 2024-03-26).
“the Company filed a certificate of amendment to the Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to effect the reverse stock split, with an effective time of 11:59 p.m., Eastern Time on March 26, 2024.”
Longeveron Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“March 4, 2024, Longeveron Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) that the Company’s Class A common stock (“Common Stock”) did not meet the $1.00 minimum bid price pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Notice does not result in the immediate delisting of the Company’s Common Stock and, pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has an initial period of 180 calendar days, or until August 31, 2024 (the “Compliance Date”), to regain complia”
Longeveron Inc. shareholders approved Approval of the Adjournment of the Special Meeting, if necessary at the 2024-02-21 meeting.
“Proposal No. 2 – Approval of the Adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are insufficient votes at the time of the Special Meeting to approve Proposal One (Reverse Stock Split Proposal). For Against Abstain Broker Non Vote 58,772,264 318,297 197,763 0”
Longeveron Inc. shareholders approved Approval of the Reverse Stock Split Proposal at the 2024-02-21 meeting.
“Proposal No. 1 – Approval of the Reverse Stock Split Proposal. For Against Abstain Broker Non Vote 58,757,459 343,463 187,442 0”
Longeveron Inc. shareholders approved Approval of the Adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are insufficient votes at the time of the Special Meeting to approve Proposal One (Warrant Exercise Proposal). at the 2023-12-26 meeting.
“Proposal No. 2 – Approval of the Adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are insufficient votes at the time of the Special Meeting to approve Proposal One (Warrant Exercise Proposal). For Against Abstain Broker Non Vote 73,258,560 94,963 6,003 0”
Longeveron Inc. shareholders approved Approval of the Issuance of up to 5,018,183 shares of Common Stock upon the exercise of warrants. at the 2023-12-26 meeting.
“Proposal No. 1 – Approval of the Issuance of up to 5,018,183 shares of Common Stock upon the exercise of warrants. For Against Abstain Broker Non Vote 73,244,407 106,707 8,413 0”
Longeveron Inc. entered into Purchase Agreement with an institutional and accredited investor valued at approximately $2.36 million (effective 2023-12-20).
“On December 20, 2023, Longeveron Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional and accredited investor (the “Purchaser”)”
Longeveron Inc. entered into Securities Purchase Agreement with Institutional and accredited investor valued at Common stock and warrants; gross proceeds approximately $4 million (effective 2023-10-11).
“On October 11, 2023, Longeveron Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional and accredited investor (the “Purchaser”) relating to the registered direct offering and sale of an aggregate of 2,365,000 shares of the Company’s Class A common stock, par value $0.001 per share (the “Common Stock”) and pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 59,243 shares of Common Stock (the “Pre-Funded Warrant Shares”) at an exercise price of $0.001 per share, at a purchase price of $1.65 per share of Common Stock and a purchase price of $1.649 per Pre-Funded Warrant (the “Offering”).”
James Clavijo departed as Interim Chief Financial Officer at Longeveron Inc..
“James Clavijo, who has been serving as interim CFO on a consulting basis while the Company searched for a permanent CFO, will step down from that interim position as of July 31, 2023”
K. Chris Min departed as Chief Medical Officer at Longeveron Inc..
“Dr. K. Chris Min, the Company’s prior CMO, stepped down effective June 30, 2023.”
Nataliya Agafonova was appointed as Chief Medical Officer at Longeveron Inc..
“Longeveron Inc. (“Longeveron” or the “Company”) has announced the appointment of Dr. Nataliya Agafonova M.D. to the Longeveron executive leadership team in the role of Chief Medical Officer (“CMO”), effective July 1, 2023.”
Longeveron Inc. shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2023-06-09 meeting.
“Proposal No. 3 - Ratification of the Appointment of Independent Registered Public Accounting Firm For Against Abstain Broker Non Vote 73,168,759 127,798 8,378 0”
Longeveron Inc. shareholders approved Approval of the Amended and Restated Longeveron Inc. 2021 Incentive Award Plan at the 2023-06-09 meeting.
“Proposal No. 2 – Approval of the Amended and Restated Longeveron Inc. 2021 Incentive Award Plan For Against Abstain Broker Non Vote 71,349,292 330,441 9,196 1,616,006”
Longeveron Inc. shareholders approved Election of Directors at the 2023-06-09 meeting.
“Proposal No. 1- Election of Directors Nominee For Withheld Broker Non Vote Wa’el Hashad 71,617,643 71,288 1,616,005 Khoso Baluch 71,617,340 71,590 1,616,005 Jeffrey Pfeffer 71,641,747 47,184 1,616,005”
James Clavijo changed role as interim Chief Financial Officer at Longeveron Inc..
“Mr. Clavijo will continue in the role of interim Chief Financial Officer beyond June 9, 2023, pursuant to the terms of a Consulting Agreement entered into by and between the Company and Mr. Clavijo, effective June 10, 2023”
Longeveron Inc. reported the first quarter ended March 31, 2023 results: revenue $0.3 million, net income $4.6 million, EPS $0.22.
“Revenue for the first quarters of 2023 and 2022 was $0.3 million and $0.4 million, respectively. Revenue consisted of: ● Clinical trial revenue, which comes from our Bahamas Registry Trial, for the three months ended March 31, 2023, and 2022 was $0.2 million and $0.3 million, respectively, representing a 23% decline, despite demand increasing in the first quarter of 2023 versus first quarter 2022. The Company experienced some discounts and one-time price adjustments that reduced overall revenue in the first quarter of 2023 for the Bahamas Registry Trial. ● Grant revenue for each of the three months ended March 31, 2023, and 2022 was $0.1 million. R&D Expenses: Research and development expenses in the first quarter 2023 were $2.8 million compared to $1.4 million for the same period in 2022. The increase of $1.4 million, or 94%, was primarily due to an increase of $1.1 million in research and development expenses that were not reimbursable by grants. Equity-based compensation allocated t”
James Clavijo resigned as Chief Financial Officer at Longeveron Inc..
“On April 4, 2023, James Clavijo, Chief Financial Officer of Longeveron Inc. (the “Company”) provided notice to the Company of his intention to resign from his position with the Company, effective June 9, 2023.”
Longeveron Inc. reported fourth quarter and full year of 2022 results: revenue Revenue in the fourth quarter 2022 was $0.1 million compared to $0.2 million in the same period in 2021. Revenue for ful, net income Net loss was $4.5 million in the fourth quarter of 2022 compared to $4.1 million for the same period in 2021. Net loss f.
“On March 10, 2023, the Company announced financial and operating results as of and for the three and twelve months ended December 31, 2022 and 2021.”
Chris Min changed role as Chief Medical Officer at Longeveron Inc..
“Dr. Chris Min, who has been serving as interim Chief Executive Officer, will continue to serve as Chief Medical Officer.”
Wa'el Hashad was appointed as Chief Executive Officer at Longeveron Inc..
“On February 22, 2023, the Board of Directors of Longeveron Inc. (the “Company”) appointed Mr. Wa’el Hashad to serve as the Company’s Chief Executive Officer, effective March 1, 2023.”
Longeveron Inc. reported third quarter ended September 30, 2022 results: revenue $0.3 million.
“Revenue for the third quarters of 2022 and 2021 was $0.3 million and $0.2 million, respectively.”
K. Chris Min was appointed as Interim Chief Executive Officer at Longeveron Inc..
“the Board of Directors has unanimously appointed K. Chris Min, M.D., Ph.D., the Company’s current Chief Medical Officer, to serve as interim Chief Executive Officer until such time as a permanent successor has been identified.”
Geoff Green resigned as Chief Executive Officer at Longeveron Inc..
“On May 3, 2022, Geoff Green, Chief Executive Officer of Longeveron Inc. (the “Company”) provided notice to the Company and Board of Directors of his intention to step down from his position, effective June 1, 2022.”
K. Chris Min, M.D., Ph.D. was appointed as Chief Medical Officer at Longeveron Inc..
“On April 5, 2022, Longeveron Inc. (“Longeveron”) announced the appointment of K. Chris Min, M.D., Ph.D. to the Longeveron executive leadership team in the role of Chief Medical Officer (CMO), effective April 4, 2022.”
Todd C. Girolamo was appointed as Class II Director at Longeveron Inc..
“On February 15, 2022, Todd C. Girolamo was appointed to the Board of Directors (the “Board”) of Longeveron Inc. (the “Company”), serving as a Class II Director with his term expiring at the Company’s 2023 annual stockholders’ meeting.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.